Jump Financial LLC Sells 477,574 Shares of Pfizer Inc. (NYSE:PFE)

Jump Financial LLC cut its position in Pfizer Inc. (NYSE:PFE) by 60.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 311,287 shares of the biopharmaceutical company’s stock after selling 477,574 shares during the period. Jump Financial LLC’s holdings in Pfizer were worth $8,258,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of PFE. Passumpsic Savings Bank boosted its holdings in Pfizer by 8.4% during the 3rd quarter. Passumpsic Savings Bank now owns 25,680 shares of the biopharmaceutical company’s stock valued at $743,000 after acquiring an additional 1,998 shares during the period. Virtu Financial LLC purchased a new stake in shares of Pfizer during the 3rd quarter valued at $1,499,000. Westside Investment Management Inc. boosted its holdings in Pfizer by 7.7% in the third quarter. Westside Investment Management Inc. now owns 14,008 shares of the biopharmaceutical company’s stock worth $404,000 after acquiring an additional 1,004 shares in the last quarter. Diamant Asset Management Inc. increased its stake in Pfizer by 8.4% during the 3rd quarter. Diamant Asset Management Inc. now owns 8,515 shares of the biopharmaceutical company’s stock valued at $246,000 after purchasing an additional 660 shares in the last quarter. Finally, Morse Asset Management Inc purchased a new position in Pfizer during the 3rd quarter worth approximately $2,649,000. 68.36% of the stock is owned by institutional investors.

Pfizer Price Performance

PFE stock opened at $22.45 on Wednesday. The stock has a 50-day moving average price of $25.09 and a two-hundred day moving average price of $26.31. The company has a market cap of $127.30 billion, a PE ratio of 15.92, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same period last year, the business earned $0.10 EPS. The business’s revenue was up 24.7% on a year-over-year basis. As a group, research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Insiders Place Their Bets

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 0.06% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on PFE. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. UBS Group reduced their price objective on Pfizer from $28.00 to $24.00 and set a “neutral” rating for the company in a research note on Tuesday, April 8th. Citigroup reissued a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. The Goldman Sachs Group reissued a “neutral” rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Finally, Truist Financial decreased their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, Pfizer has an average rating of “Moderate Buy” and an average target price of $31.07.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.